ATE298323T1 - Hemmer der verzweigtenaminosäure-abhängigen aminotransferase und deren verwendung in der behandlung von neurodegenerativen erkrankungen - Google Patents

Hemmer der verzweigtenaminosäure-abhängigen aminotransferase und deren verwendung in der behandlung von neurodegenerativen erkrankungen

Info

Publication number: ATE298323T1
Authority: AT; Austria
Prior art keywords: treating; disease; neurodegenerative diseases; treatment; amino acid
Prior art date: 2000-09-19

Application number

AT01964182T

Other languages

English (en)

Inventor

Keenan Martin Bora

Lain-Yen Hu

Suzanne Ross Kesten

Huanyshu Lei

David Winslow Moreland

Michael Francis Rafferty

Todd Robert Ryder

Jeffrey David Scholten

David Juergen Wustrow

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-19

Filing date

2001-08-17

Publication date

2005-07-15

2001-08-17 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2005-07-15 Application granted granted Critical

2005-07-15 Publication of ATE298323T1 publication Critical patent/ATE298323T1/de

Links

208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
-1 AMINO Chemical class 0.000 title 1
239000002380 aminotransferase inhibitor Substances 0.000 title 1
230000004770 neurodegeneration Effects 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010002091 Anaesthesia Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
101710105312 Branched-chain-amino-acid aminotransferase Proteins 0.000 abstract 1
101710097328 Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 abstract 1
101710194298 Branched-chain-amino-acid aminotransferase, mitochondrial Proteins 0.000 abstract 1
208000000094 Chronic Pain Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 abstract 1
206010011878 Deafness Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
201000010374 Down Syndrome Diseases 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
208000013016 Hypoglycemia Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
101710158343 Probable branched-chain-amino-acid aminotransferase Proteins 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
101710199693 Putative branched-chain-amino-acid aminotransferase Proteins 0.000 abstract 1
206010044688 Trisomy 21 Diseases 0.000 abstract 1
206010046543 Urinary incontinence Diseases 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
239000002647 aminoglycoside antibiotic agent Substances 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
230000037005 anaesthesia Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
AZPBDRUPTRGILK-UHFFFAOYSA-N benzotriazol-1-ium-1-ylidenemethanediamine;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=CC=C2N(C(=N)N)N=NC2=C1 AZPBDRUPTRGILK-UHFFFAOYSA-N 0.000 abstract 1
230000019771 cognition Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000036461 convulsion Effects 0.000 abstract 1
208000001763 cytomegalovirus retinitis Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
239000003257 excitatory amino acid Substances 0.000 abstract 1
230000002461 excitatory amino acid Effects 0.000 abstract 1
230000010370 hearing loss Effects 0.000 abstract 1
231100000888 hearing loss Toxicity 0.000 abstract 1
208000016354 hearing loss disease Diseases 0.000 abstract 1
230000002218 hypoglycaemic effect Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
208000004296 neuralgia Diseases 0.000 abstract 1
208000021722 neuropathic pain Diseases 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
- C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Quinoline Compounds (AREA)

AT01964182T 2000-09-19 2001-08-17 Hemmer der verzweigtenaminosäure-abhängigen aminotransferase und deren verwendung in der behandlung von neurodegenerativen erkrankungen ATE298323T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23378600P	2000-09-19	2000-09-19
PCT/US2001/025892 WO2002024672A2 (en)	2000-09-19	2001-08-17	Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases

Publications (1)

Publication Number	Publication Date
ATE298323T1 true ATE298323T1 (de)	2005-07-15

Family

ID=22878678

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01964182T ATE298323T1 (de)	2000-09-19	2001-08-17	Hemmer der verzweigtenaminosäure-abhängigen aminotransferase und deren verwendung in der behandlung von neurodegenerativen erkrankungen

Country Status (17)

Country	Link
US (1)	US20050004167A1 (de)
EP (1)	EP1320523B1 (de)
JP (1)	JP2004509880A (de)
AT (1)	ATE298323T1 (de)
AU (1)	AU2001285067A1 (de)
BR (1)	BR0113974A (de)
CA (1)	CA2416136A1 (de)
DE (1)	DE60111639T2 (de)
DO (1)	DOP2001000250A (de)
ES (1)	ES2241861T3 (de)
GT (1)	GT200100188A (de)
MX (1)	MXPA03001277A (de)
PA (1)	PA8528901A1 (de)
PE (1)	PE20020362A1 (de)
TN (1)	TNSN01135A1 (de)
UY (1)	UY26939A1 (de)
WO (1)	WO2002024672A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA02010430A (es) *	2001-11-27	2003-06-02	Warner Lambert Co	Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
MXPA02010231A (es)	2001-11-27	2004-12-13	Warner Lambert Co	Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US7435837B2 (en)	2003-10-24	2008-10-14	Wyeth	Dihydrobenzofuranyl alkanamine derivatives and methods for using same
FR2862646B1 (fr) *	2003-11-20	2006-02-24	Merck Sante Sas	Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
JP2007527903A (ja) *	2004-03-08	2007-10-04	プロシディオン・リミテッド	インドール−２−カルボン酸ヒドラジド化合物
US10941109B2 (en)	2011-06-13	2021-03-09	Ergon Pharmaceuticals Llc	Compositions and methods of treatment using a BCAT1 inhibitor
US9422224B2 (en) *	2011-06-13	2016-08-23	Ergon Pharmaceuticals Llc	Methods of treatment using a BCAT1 inhibitor
EP3445369B1 (de) *	2016-04-21	2026-03-25	Eip Pharma, LLC	Vx-745 zur verwendung bei der behandlung von demenz
US11466008B2 (en)	2017-09-18	2022-10-11	Eip Pharma, Llc	Co-crystals of neflamapimod (VX-745)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0224823A3 (de) *	1985-11-26	1988-02-10	BASF Aktiengesellschaft	Chinolinderivate und ihre Verwendung zur Bekämpfung von unerwümschtem Pflanzenwachstum
DE3606949A1 (de) *	1986-03-04	1987-09-10	Basf Ag	Chinolinderivate und ihre verwendung zur bekaempfung von unerwuenschtem pflanzenwachstum
DE69405535T2 (de) *	1994-03-11	1998-04-02	Agfa Gevaert Nv	Photographisches Material, das einen neuen Typ eines Hydrazides enthält

2001
- 2001-08-17 AT AT01964182T patent/ATE298323T1/de not_active IP Right Cessation
- 2001-08-17 MX MXPA03001277A patent/MXPA03001277A/es not_active Application Discontinuation
- 2001-08-17 DE DE60111639T patent/DE60111639T2/de not_active Expired - Fee Related
- 2001-08-17 WO PCT/US2001/025892 patent/WO2002024672A2/en not_active Ceased
- 2001-08-17 BR BR0113974-6A patent/BR0113974A/pt not_active IP Right Cessation
- 2001-08-17 JP JP2002529082A patent/JP2004509880A/ja active Pending
- 2001-08-17 AU AU2001285067A patent/AU2001285067A1/en not_active Abandoned
- 2001-08-17 EP EP01964182A patent/EP1320523B1/de not_active Expired - Lifetime
- 2001-08-17 CA CA002416136A patent/CA2416136A1/en not_active Abandoned
- 2001-08-17 ES ES01964182T patent/ES2241861T3/es not_active Expired - Lifetime
- 2001-09-07 PE PE2001000902A patent/PE20020362A1/es not_active Application Discontinuation
- 2001-09-12 GT GT200100188A patent/GT200100188A/es unknown
- 2001-09-17 UY UY26939A patent/UY26939A1/es not_active Application Discontinuation
- 2001-09-18 TN TNTNSN01135A patent/TNSN01135A1/fr unknown
- 2001-09-19 PA PA20018528901A patent/PA8528901A1/es unknown
- 2001-09-20 DO DO2001000250A patent/DOP2001000250A/es unknown
2004
- 2004-01-26 US US10/765,002 patent/US20050004167A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2002024672A2 (en)	2002-03-28
DE60111639T2 (de)	2006-04-27
WO2002024672A3 (en)	2003-03-06
JP2004509880A (ja)	2004-04-02
UY26939A1 (es)	2002-04-26
TNSN01135A1 (fr)	2005-11-10
PE20020362A1 (es)	2002-05-11
GT200100188A (es)	2002-04-22
MXPA03001277A (es)	2004-07-30
AU2001285067A1 (en)	2002-04-02
DE60111639D1 (de)	2005-07-28
EP1320523A2 (de)	2003-06-25
US20050004167A1 (en)	2005-01-06
PA8528901A1 (es)	2003-02-14
DOP2001000250A (es)	2002-06-15
CA2416136A1 (en)	2002-03-28
EP1320523B1 (de)	2005-06-22
ES2241861T3 (es)	2005-11-01
BR0113974A (pt)	2003-07-01

Legal Events

Date	Code	Title	Description
2005-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
MXPA02010231A (es)	2004-12-13	Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
UY26813A1 (es)	2002-01-31	Compuestos para tratar enfermedad de alzheimer
MXPA05011150A (es)	2005-12-14	2-hidroxi-3-diaminoalcanos de benzamida.
DE69111642D1 (de)	1995-09-07	Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten.
MXPA04002785A (es)	2004-07-29	Aminas sustituidas para tratamiento de enfermedad de alzheimer.
MXPA05002420A (es)	2005-10-05	Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
DE60316779D1 (de)	2007-11-22	Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE60111639D1 (de)	2005-07-28	Hemmer der verzweigtenaminosäure-abhängigen aminotransferase und deren verwendung in der behandlung von neurodegenerativen erkrankungen
AU2002314914A1 (en)	2002-12-16	Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
EP1689713A4 (de)	2009-02-18	Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NL300175I1 (nl)	2005-04-01	Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
ATE359794T1 (de)	2007-05-15	3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
EP0699439A3 (de)	1996-06-26	Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase
ATE357453T1 (de)	2007-04-15	Comt-inhibitoren
MXPA03011521A (es)	2004-03-18	Aminadioles para tratamiento de enfermedad de alzheimer.
DE60234919D1 (de)	2010-02-11	3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
DE602004023762D1 (de)	2009-12-03	Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
MX2023007287A (es)	2023-07-03	N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas.
ATE506061T1 (de)	2011-05-15	Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien
MXPA02011921A (es)	2003-04-22	Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
ATE317696T1 (de)	2006-03-15	Inhibitore der verzweigte-aminosäure-abhängigen aminotransferase und deren verwendung in der behandlung von neurodegenerativen erkrankungen
IL178167A0 (en)	2006-12-31	1,3,4-oxadiazol-2-ones as ppar delta modulators
EA202191521A1 (ru)	2021-09-10	2-фторированные желчные кислоты для лечения нейродегенеративных заболеваний
ATE359995T1 (de)	2007-05-15	Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
DE602004031225D1 (de)	2011-03-10	3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks